Poliomyelitis is a severe infectious disease that can greatly affect the health of children. Extensive global use of live attenuated oral polio vaccine (OPV) since the 1960s [1, 2] and the gradual replacement of OPV with the conventional inactivated polio vaccine (IPV) derived from a wild strain (Salk-IPV) in developed countries since the 1950s [3] [4] [5] has substantially achieved the global control and elimination of poliomyelitis as part of global public health strategies for the control of important infectious diseases [6, 7] .The new World Health Organization (WHO) Global Polio Eradication and Endgame Strategic Plan 2013-2018 endorsed by the World Health Assembly aims to completely eradicate polio caused by wild poliovirus infection as well as vaccine-associated paralytic poliomyelitis (VAPP) and disease caused by either circulating vaccine-derived polioviruses (cVDPVs) or immunodeficiency-associated VDPVs (iVDPVs) [8] [9] [10] . Based on review of these risks from continued use of OPV, a new global action plan is being implemented to systematically replace OPV with IPV, and include the introduction of Sabin strain-based IPV (Sabin-IPV) for new vaccine manufacturing [11, 12] . Sabin-IPV has been approved for use in several countries based on the neutralizing capacity of serum from immunized children against multiple polioviruses [13] . The efficacy of OPV is supported by substantial, long-term epidemiological data [14] . However, based on differences in viral structure, Sabin strains can be expected to have different antigenicity than wild strains [15, 16] , and changes in the antigenic structure during the inactivation process remain largely unknown. We conducted clinical trials of Sabin-IPV in regions without clinical polio epidemics. Cross-neutralization assays of sera collected from human subjects immunized with Sabin-IPV were tested against multiple strains of wild poliovirus, cVDPVs, and iVDPVs to determine if the immune response induced by Sabin-IPV immunization could provide evidence of immunologically relevant protection. The results demonstrated that the M A J O R A R T I C L E use of Sabin-IPV for routine immunization can provide protection against multiple poliovirus strains that may be present in the environment.
MATERIALS AND METHODS

Ethics Statement and Consent to Participate
The protocol for the clinical trial (Supplementary File 1) and informed consent form (Supplementary File 2) were reviewed by the Guangxi Ethics Committee (IRB00001594; FWA00001359). Five committees from Guangxi Institutional Review Board approved the study. All the enrolled subjects of this clinical trial were requested to provide written informed consent.
Preparation of the Sabin Strain-Based Inactivated Vaccine and Subject Immunization
Sabin-IPV was prepared from live attenuated poliovirus strains grown in Vero cells using microcarrier technology. The working seed lots included type I, Sabin SO+2; type II, Sabin SO+2; and type III, Pfizer RSO2 [17] . After purification of the virus suspension and subsequent inactivation by formalin, 3 groups of vaccines were formulated based upon D antigen quantitation by an enzyme-linked immunosorbent assay (ELISA): the high-dose group (type I, 45 D-antigen unit [DU]/dose; type II, 64 DU/dose; type III, 67.5 DU/dose), the medium-dose group (30 DU/dose, 32 DU/dose, 45 DU/dose) and the low-dose group (15 DU/dose, 16 DU/dose, 22.5 DU/dose) as previously described [18, 19] . The vaccines in these groups were qualified by the National Institutes for Food and Drug Control (approval numbers SZ200803653, SZ200803652, and SZ200803891). Each dose was injected at 2, 3, and 4 months of age according to the immunization schedule used for Salk-IPV in the phase 2 trial [20] .
Experimental Design
The immune sera used in this study were collected from vaccinated subjects in the phase 2 trial with the approval number 2007L02021 by the Chinese Food and Drug Administration (ClinicalTrials.gov identifier NCT01056705). This trial was conducted based upon blinded randomization and positive control design in Pingle County, Guilin City of Guangxi Zhuang Autonomous Region. The trial was designed by the Institute of Medical Biology, the Chinese Academy of Medical Biology and the Center for Disease Control and Prevention, Guangxi Zhuang Autonomous Region (Guangxi CDC), and monitored by Beijing Simoon record Pharma, an independent contract research organization (www.simoonrecord.com). A total of 500 healthy infants were randomly assigned to 1 of the 5 groups: A, B, C, D, and E. Groups A, B, and C received 3 doses of Sabin-IPV with high, medium, and low D antigen content, respectively, at 2, 3, and 4 months of age. Groups D and E were used as controls and received 3 doses of regular OPV or Salk-IPV, respectively, on the same schedule [20] . The serum samples were taken from each of the 5 vaccinated groups 1 month after the third dose of primary immunization series, of which 50 samples were randomly selected from each group for cross-neutralization assay using Microsoft Excel software by the statistician under the supervision of the contract research organization [21] (Figure 1 ).
Viruses and Cells
A total of 19 poliovirus strains were used in this study (Supplementary File 3) . The Xinjiang epidemic poliovirus was obtained from Chinese CDC. The other 18 poliovirus strains of all 3 serotypes, including live attenuated vaccine strains, reference wild strains, current wild circulating strains, cVDPVs, and iVDPVs were all part of the collection at the US Centers for Disease Control and Prevention (US CDC). All virus stocks were prepared and titers obtained in triplicate. Vero cells of WHO seed P134 10-87 were obtained from the European Collection of Cell Cultures.
Cross-Neutralization Assay
Each serum was tested by cross-neutralizing assays to 19 poliovirus strains, including 18 individual representative poliovirus strains (starting dilution 1:32) and the Xinjiang 2011 epidemic strain (starting dilution 1:8). Neutralizing antibody testing was performed using the WHO standard protocol. In brief, diluted serum was mixed with an equal volume of medium containing 100 cell-culture infectious dose 50% (CCID 50 ) of poliovirus in 96-well plates and incubated for 2 hours at 37°C, followed by the addition of 0.1 mL of Hep-2 cell suspension (2 × 10 4 cells).
After incubation for 5 days at 36°C, the cytopathic effect of viral infection was examined. The serum antibody titer is the highest dilution of serum that protects 50% of the culture against 100 CCID 50 of viral challenge [22] .
Comparison of Gene Sequences From Poliovirus Strains
The sequences of the polioviruses were obtained from the US CDC and the Chinese CDC using standard procedures. The genetic sequences of the VP1, 2, and 3 genes in the main neutralizing epitopes were investigated using the program CLUSTAL_X 1.8.
Statistical Analysis
Statistical analysis was performed using SPSS 16.0 (IBM SPSS, Chicago, Illinois). The geometric mean titer (GMT) of neutralizing antibody against each viral strain was calculated as below, each neutralizing titer obtained was converted to lg value (X) followed by substituting it into formula of GMT = lg -1 (ΣlgX/n). Pearson χ 2 analysis was used with the formula of Χ 2 = n(ΣA 2 / n R n C -1), ν = (R-1)(C-1), where A is the actual frequence frequency, R is the line number, and C is the column number). We assigned the reciprocal antibody titers below the limit of detection (1:23) an arbitrary value of 1, except for 1:8 in the case of Xinjiang 2011.
RESULTS
Participants Included in the Study
Fifty serum samples were randomly selected from the each of these 5 vaccination groups, including low, middle, and high Sabin-IPV antigen doses and OPV and Salk-IPV controls as indicated in Figure 1 .
Neutralizing Antibodies Against Sabin and Wild Poliovirus Strains Exhibit Varying Titers
To explore the potential occurrence of antigenicity alterations during the inactivation process, we first investigated the neutralizing capacity of Sabin-IPV immune sera against Sabin and other wild strains ( Table 1 ). The neutralizing antibodies exhibited identical reactivities against the 3 types of live attenuated Sabin strains and the wild poliovirus strains ( Figure  2 ). However, due to variations in antigen content, higher GMTs were observed in the high-dose group compared to the low-dose group (4372 vs 263). Similar reactivities of the Salk-IPV immune serum against the Sabin and wild strains were observed for the high-dose Sabin-IPV group (Figure 2 ), although the reactivity of anti-serum type I of Salk-IPV to the Sabin strain tended to be lower ( Figure 2A ). The neutralizing capacities of the control OPV immune serum against the Sabin and wild strains followed a pattern with slight variation to that of the immune sera of Salk-IPV and high-dose Sabin-IPV ( Figure 2 ).
Neutralizing Capacity of Immune Sera From Different Groups Against Recently Circulating Wild Strains of Types I and III
Recent molecular biology studies of pandemic wild poliovirus strains have revealed variations in the antigen structures of pandemic strains identified before and after the use of vaccines in some regions of the world. This variation is presumed to be triggered primarily by long-term immune pressure in populations immunized universally with OPV or IPV [23, 24] . These pandemic poliovirus strains play an essential role in efficacy studies in Sabin-IPV clinical trials. In the current study, the neutralizing capacities of individual Sabin-IPV, OPV, and Salk-IPV immune sera against 5 wild poliovirus strains (3 of type I and 2 of type III) isolated from polio patients in different regions in the world were determined ( Table 1 ). The neutralizing capacities of sera from human subjects immunized with Sabin-IPV, Salk-IPV, and OPV against pandemic wild poliovirus strains were similar ( Figure 3) . A neutralization assay of Sabin-IPV serum against the XJ epidemic wild strain isolated from a patient during the Xinjiang epidemic polio in 2011 [25] revealed lower reactivity of the immune sera obtained from the low-dose group, but higher or closer in high-or middle-doses groups compared with that of Salk-IPV ( Figure 3C ).
Reactivity of Sabin-IPV Immune Serum Against Multiple VDPV Strains
In the post-polio eradication era, the most important reason for the gradual replacement of OPV with IPV for routine immunization is to protect against VAPPs potentially arising from OPV-immunized populations, regardless of the much lower rate of development [26] . Thus, the ability of the Sabin-IPV immune serum to recognize and, consequently, neutralize VDPVs frequently identified as major causative pathogens of VAPPs is a crucial component of the evaluation of the efficacy of Sabin-IPV. Again, as demonstrated in the neutralization assay, the Sabin-IPV, Salk-IPV, and OPV immune sera exhibited equally remarkable reactivities against 6 individual cVDPVs and iVDPVs isolated from multiple VAPPs (Figure 4 ). However, in the neutralization assay for one iVDPV strain of type II, slight reactivity with the OPV immune serum was observed; by contrast, no reactivity was noted between the virus and the Sabin-IPV and Salk-IPV immune sera ( Figure 4D ). This VDPV strain may be a representative node in poliovirus evolution in vaccine-immunized populations, a phenomenon that would pose a new challenge for the practical use of polio vaccines.
DISCUSSION
Poliomyelitis, a highly infectious disease that seriously threatens human health worldwide [27] , has been dramatically eliminated in recent decades due to the persistent implementation of the WHO's Global Polio Eradication program comprising the combined use of OPV and IPV among children [28, 29] . A future post-polio eradication era is anticipated [30] . With the implementation of the polio-eradication strategic plan, the distribution of poliovirus in nature comprises a majority of live attenuated vaccine strains in combination with a small number of potential wild strains [31] . This epidemiologically significant pathogenic characterization may lead to stricter requirements on the use of vaccines based on 2 principles: (1) to further reduce the transmission of wild polioviruses in the environment and (2) to gradually reduce and finally stop the circulation of live attenuated vaccine strains among populations [32] . In this context, the use of Sabin-IPV is of practical significance. Although there are significant difficulties in identifying human populations without polio outbreaks for clinical trials, such clinical trials are a prerequisite for the approval of vaccine use based on standard efficacy evaluations. Fortunately, our clinical trials have sufficiently demonstrated the efficacy and safety of Sabin-IPV [18] . Furthermore, with financial support from the Gates Foundation and WHO, we explored the reactivities induced by the Sabin-IPV immune serum against different poliovirus strains. b For XJ strain, the seroconversion rate is the rate of those whose antibody titer was ≥8.
Previous data indicated that the Sabin strains for the preparation of polio live attenuated vaccines are originated from the wild Mahoney strain for type I, P712 strain for type II, and Leon strain for type III [33] . This means that live attenuated strains have maintained the basic antigenic characteristics of the primary virus strain [34] . Here, a cross-neutralization study to 19 strains including live attenuated vaccine strains, wild strains, wild circulating strains, cVDPVs, and iVDPVs was conducted with the sera from subjects enrolled in a phase 2 trial, in which, these subjects were immunized with primary immunization neutralization were 178.9, 427.6, and 610.2 for Sabin I, Sabin II, and Pfizer and 360.4, 666.3, and 500.2 for Mahoney, MEF, and Saukett; the GMTs of high-dose Sabin-IPV immune serum neutralization were 4371.7, 1332.2, and 887.5 for Sabin I, Sabin II, and Pfizer and 363.8, 380.8, and 313.9 for Mahoney, MEF, and Saukett. Thus, the reactivity potency of the Sabin-IPV high-dose immune serum was similar to that of Salk-IPV immune serum. The neutralization capacities of Sabin-IPV immune serum from the medium-and low-dose groups against the 3 individual wild poliovirus strains tended to gradually decrease, suggesting that the Sabin-IPV and Salk-IPV immune sera could bind all of the wild poliovirus strains to subsequently neutralize virus infectivity. The Sabin-IPV and Salk-IPV immune sera interacted similarly with the wild poliovirus type I and III strains isolated from recent epidemic polio-infected populations, indicating that these 2 vaccines should induce similar immune protection against current wild poliovirus strains. These 2 vaccines exhibited the same neutralization capacities against the wild poliovirus type I strain isolated from the Xinjiang epidemic polio in 2011, although the Sabin-IPV immune serum obtained from the low-dose group exhibited distinctly lower neutralizing reactivity. The immune sera for the 2 vaccines exhibited similar reactivities against the majority of the 3 types of VDPVs.
An exception was that the GMTs of the neutralization of one iVDPV strain of type 2 by the Salk-IPV and Sabin-IPV immune sera were unexpectedly lower than 2, whereas the GMT of OPV immune serum was 16. Whether this finding is an exception or significant requires further investigation from the perspective of polio vaccine research and disease control. Prior to these results and the comparison analysis of the antigen structure of polioviruses, the sequences of amino acids in the major antigen structural regions were determined to be highly conserved, with the exception of some variations in important gene loci (eg, the noncoding region, which functions in translation and replication initiation, between wild strains and live attenuated strains, or the vast majority of VDPVs). This homology is presumably responsible for the cross-reactivity of the Sabin-IPV and Salk-IPV immune sera against wild strains, live attenuated strains, and VDPVs. Clearly, the above-mentioned iVDPV strain of type II is an exceptional example that merits further investigation.
CONCLUSIONS
In evaluation of immune efficacy of Sabin strain-based IPV in immunized children, our cross-neutralization assay here suggested that the neutralizing antibody response induced by this vaccine is available to all epidemic wild poliovirus strains and most vaccine-derived poliovirus strains, with rare exceptions.
